World-renowened researchers, physicians, clinicians and students presented their cancer immunotherapy research in oral and poster abstract presentations at the annual Society for Immunotherapy of Cancer (SITC) meeting.
Experts from Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, were there, contributing to 20 abstracts selected for poster presentations.
Also, Bernard Fox, Ph.D., a Harder Family Endowed Chair for Cancer Research and leader of the Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, received the 2024 SITC Lifetime Achievement Award.
Find out more and read abstracts by our researchers and oncologists.
Category: Biomarkers, Immune Monitoring and Novel Technologies
Abstract 156: Dark immunopeptidome of head and neck squamous cell carcinoma in serial cell lines from a single patient during multimodality treatment time-course
Presenting Author: Ryan Meng
Authors: Ryan Meng, Tarsem Moudgil, Noriko Iwamoto, Yuriko Minegishi, Yoshinobu Koguchi, Venkatesh Rajamanickam, Tanisha Christie, Eric Tran, William Redmond, Carlo Bifulco, Traci Hilton, Alexa Dowdell, Shawn Jensen, Christopher Paustian, Ashish Patel, Hong-Ming Hu, R. Bryan Bell, Walter Urba, Koji Ueda, Takashi Shimada, Brian Piening, Rom Leidner
Authors: Noriko Iwamoto, Eric Tran, Yi-Ping Shih, Yoshinobu Koguchi, Takashi Shimada
Category: Clinical Trials in Progress
Abstract 1481: Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy
Presenting Author: Rom Leidner
Authors: Rom Leidner, Christopher Paustian, Shawn Jensen, Tarsem Moudgil, Noah Simons, Yoshinobu Koguchi, Venkatesh Rajamanickam, Dennis Nijenhuis, Ryan Meng, Marcus Couey, Quyen Vu, Matthew Taylor, Lakhvir Kaur, Brady Bernard, Tanisha Christie, Noriko Iwamoto, Yuriko Minegishi, Koji Ueda, Annie Long, Patrick Rethwisch, Robert Hermann, William Redmond
Abstract 672: The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study
Authors: Brendan Curti, Devalingam Mahalingam, Mateusz Opyrchal, Justin Moser, Ildefonso Rodriguez Rivera, Mehmet Bilen, Christos Fountzilas, Kristin Morris, Christopher Nirschl, Shawn Ironside, Saero Park, Marissa Bruno, Paul Windt, Kulandayan Subramanian, Sameer Chopra, Randi Isaacs, Jason Luke
Abstract 677: A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
Authors: Brendan Curti, Jong Chul Park, Marcus Butler, i, Gail Iodice, Danielle Pastor, Joseph Elassal, Howard Kaufman, John Kirkwood
Abstract 662: A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumors
Authors: Rom Leidner, Shaunica Mitchell, Binaish Khan, Francis Payumo, E. Gabriela Chiorean, Zhubin Gahvari, J. Hecht, Michael Hurwitz, Heinz-Josef Lenz, Meredith Pelster, Adam Schoenfeld, Salman Punekar, Dan Zhao, Soumit Basu, Dirk Nagorsen
Abstract 656: A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression
Authors: Rachel Sanborn, Prantesh Jain, Alissa Cooper, Melissa Johnson, Erin Schenk, , Jonathan Thompson, Hirva Mamdani, Afshin Dowlati, Rahul Aggarwal, Kamya Sankar, Ann Gramza, Himisha Beltran
Authors: Rom S Leidner, Iben Spanggaard, Matteo Morotti, Paul L Swiecicki, Matteo Simonelli, Guillermo Suay Montagut6, Guillermo De Velasco, Oria de Rueda, Juan Martin-Liberal, Alberto Hernando Calvo, Nuria Kotecki, Nikolina Vachtsevanou, Melissa Vrohlings, Clare Price, Daniel Lenherr-Frey, Christian Leisner, Leonardo Borras, Rouven Bingel-Erlenmeyer, Swethajit Biswas, Hans Prenen, Giuseppe Curigliano, Jean-Pascal Machiels, Gilberto Lopes, Mark Diamond and Emiliano Calvo
Category: Cellular Therapies
Abstract 322: ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated safety and efficacy from the phase 1 TRAVERSE multicenter study
Authors: Brendan Curti, Samer Srour, Jad Chahoud, Alexandra Drakaki, Sumanta Pal, Lily Tang, Sacha Prashad, Joy Atwell, Chelsea Williams, Srinivas Ghatta, Chris Severyn, John Le Gall, Nizar Tannir, Ritesh Kotecha
Abstract 446: Developmental and functional differences between CD39+CD103+ DP CD8 T cells from normal colon and tumor in CRC patients
Named “Top 100 Abstracts”
Presenting Author: Thomas Duhen
Authors: Thomas Duhen, Olivier Fesneau, Wesley Rosales, Kimberly Samson, Venkatesh Rajamanickam
Category: Clinical Trials Completed
Abstract 1505: Phase I/II study of Safety and Efficacy of Intraperitoneal IMNN-001 with Neoadjuvant Chemotherapy of Paclitaxel and Carboplatin in Patients Newly Diagnosed with Advanced Epithelial Ovarian Cancer
Authors: Christopher Darus, Premal Thaker, Debra Richardson, Andrea Hagemann, Robert Holloway, Mark Reed, Melanie Bergman, Bhavana Pothuri, Stephen DePasquale, Jennifer Scalici, Amy Bregar, , Karen Finkelstein, Charles Leath, Maria Bell, David Warshal, Richy Agajanian, Megan Indermaur, Alberto Mendivil, Diane Provencher, Nicholas Borys, Sebastien Haz
Category: Machine Learning, Artificial Intelligence and Computational Modeling
Abstract 1237: Deep Learning Serial CT Response Score Predicts Overall Survival in Advanced NSCLC Treated with PD-(L)1 Immune Checkpoint Inhibitors
Authors: Brendan Curti, Chiharu Sako, Taly Schmidt, Arpan Patel, Dwight Owen, Arya Amini, Ronan Kelly, Ray Page, Aurelie Swalduz, Jean-Paul Beregi, Jan Chrusciel, Stephane Sanchez, Richard Rosenberg, Eric Snyder, Jakob Weiss, Andrew Wentland, Anish Kirpalani, An Liu, Olivier Gevaert, George Simon, Hugo Aerts, Ravi Parikh, Petr Jordan
Category: Immune Cell Types and Biology
Abstract 919: IL-12 induces the expression of the immune checkpoint NKG2A on human tumor reactive CD8 TILs
Presenting Author: Olivier Feneau
Authors: Olivier Fesneau, Thomas Duhen, Wesley Rosales, Kimberly Samson, Tarsem Mougdil, Venkatesh Rajamanickam
Category: Combination Immunotherapies
Abstract 715: Combining a complex cancer vaccine with anti-PD-1 and DGK inhibitor Improves therapeutic efficacy and may augment anti-cancer memory development
Authors: Bernard Fox, Elie Adwani, Shawn Jensen
Abstract 778: Phase 1b study of dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with non-small-cell lung cancer, triple-negative breast cancer, or head and neck squamous-cell carcinoma
Authors: David Page, Benjamin Cooper, Daniel Olson, Wade Iams, Yuan Yuan, Naamit Gerber, John Gibbs, Richard Gregory, Kwok-Kin Wong, Jiehui Deng, Samanthi Perera, Kai Ding, Emily Roberts, Allison Berger, Camilla Christensen Ross, Erica Xin Tong, Angel Maldonado Lopez, Vicky Appleman, E. Jane Leonard, Alex Parent, Harry Yu-Chung Huang, Camden Bay
Category: Novel Single-Agent Immunotherapies
Abstract 1301: Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
Presenting Author: Nisha Holay
Authors: Nisha Holay, William Redmond, Melissa Kasiewicz, Rashi Yadav, Annah Rolig, Yaiza Diaz-De-Durana
Abstract 1310: Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B inhibitor
Authors: Rachel Sanborn, Jason Luke, Hadi Danaee, Samira Jaeger, Kim Robell, Wei Liu, Manish Patel, Jordi Rodon, Kyaw Thein, Claire Friedman, David Levitz, Daniel Pointing, Mark Uhlik, Yilin Qi, Fang Wang, Yingzhi Bi, Ken Carson, Jun Kuai, Gerry Harriman, Timothy Reilly, Amanda Redig
Category: Checkpoint Blockade Therapy
Abstract 497: Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors
Authors: Matthew Taylor, Jacob Thomas, J. Eva Selfridge, Costantine Albany, Inderjit Mehmi, Vineet Kwatra, Siwen Hu-Lieskovan, Paul de Souza, Ankit Mangla, Judith Llorin-Sangalang, Kartik Aysola, Omid Hamid
Category: Immuno-Engineering
Abstract 1109: Engineering T-cells with CD40-based chimeric receptors to enhance adoptive T-cell therapy
Presenting Author: Myungkyu Jang
Authors: Myungkyu Jang, Eric Tran
Category: Immune Stimulants and Immune Modulators
Abstract 1007: Modulating CAF phenotypes in pancreatic cancer to enhance formation of tertiary lymphoid structures
Authors: Kristina Young, Wei Chen, Elijah Kirschstein, Olivia Harder, Shrijan Khanal, Andrew Gunderson, Morgan Mack, Carl Ware
To learn more about Earle A. Chiles Research Institute:
- Visit our website.
- Follow us on Twitter, LinkedIn and Facebook.
- Read our blog for the latest news and announcements.
Related news
Harnessing CAR T-cell therapy: A new study for indolent B-cell non-Hodgkin lymphoma
New studies test immunotherapy to boost breast cancer treatment and prevent return
Dr. Bernard Fox honored for his lifetime contributions to cancer research
